PAP
BBIO icon

Persistent Asset Partners’s BridgeBio Pharma BBIO Stock Holding History

Persistent Asset Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-536
Closed -$72K – 347
2025
Q4 		$72K Buy
+536
New +$35.2K 0.03% 282

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Persistent Asset Partners's BBIO Position: Q1 2026 in Review

Persistent Asset Partners increased its BridgeBio Pharma (BBIO) stake by 27% in Q1 2026, buying an estimated $371K and bringing the position to 23,810 shares worth $1.77M. The position accounts for 0.66% of the portfolio, ranked #37.

Persistent Asset Partners first reported a position in BBIO in Q4 2025 and has held it in 2 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Persistent Asset Partners held 23,810 shares of BridgeBio Pharma worth $1.77M as of Q1 2026.
  • Persistent Asset Partners bought 5,114 BridgeBio Pharma shares in Q1 2026, an estimated $371K.
  • BridgeBio Pharma made up 0.66% of Persistent Asset Partners's portfolio in Q1 2026, its #37 holding.
  • Persistent Asset Partners first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 2 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.